medigraphic.com
ISSN 0185-3325 (Impreso)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2004, Número 5

Siguiente >>

Salud Mental 2004; 27 (5)


The concept of melancholia and antidepressant treatment

Kragh-Sørensen P, Bjerregaard SK

Idioma: Ingles.
Referencias bibliográficas: 35
Paginas: 1-7
Archivo PDF: 71.67 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders. 3rd edition (DSMIII). Washington, 1980.

  2. BERTELSEN A: Reflections on the clinical utility of the ICD-10 and DSM-IV classifications and their diagnostic criteria. Australian New Zealand J Psychiatry, 33:166-173, 1999.

  3. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders. 4th edition (DSM-IV). Washington, 1994.

  4. WORLD HEALTH ORGANIZATION: The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research, Geneva, 1993.

  5. KRAEPELIN E: Psychiatrie. Ein Lehrbuch Für Studierende und Ärzte. 6. ed. Verlag von Johann Ambrosius Barth, Leipzig, 1899.

  6. HEALY D: The Antidepressant Era. Harvard University Press. Cambridge and London, 1997.

  7. BALDWIN D, THOMSON C: The future of antidepressant pharmacotherapy. World Psychiatry, 2(1):3-8, 2003.

  8. KIRSCH I, MOORE TJ, SCOBORIA A, NICHOLLS SS: The Emperor’s new drugs: an analysis of antidepressant medication data submitted to the US food and drug administration. Prevention Treatment, 5(23), July 15, 2002.

  9. KIRSCH I, SAPIRSTEIN G: Listening to Prozac but Hearing Placebo: A Meta-Analysis of Antidepressant Medication. Prevention Treatment, 1(0002a):1-13, June 26, 1998.

  10. MONCRIEFF J: The antidepressant debate. Editorial. British J Psychiatry, 180: 193-194, 2002.

  11. PARKER G: (Editorial) ‘New’ and ‘old’ antidepressants: all equal in the eyes of the lore? British J Psychiatry, 179:95-96, 2001.

  12. THASE ME: Antidepressant effects: The suit may be small, but the fabric is real. Prevention Treatment, 5(32), July 15, 2002.

  13. WALSH BT, SEIDMAN SN, SYSKO R, GOULD M: Placebo response in studies of major depression. Variable, substantial, and growing. JAMA, 287(14): 1840-1847, 2002.

  14. ZIMMERMAN M, MATTIA JI, POSTERNAK MA: Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice. Am J Psychiatry, 159:469-473, 2002.

  15. AMERICAN PSYCHIATRIC ASSOCIATION: Practice guidelines for the treatment of psychiatric disorders. Compendium, 507-508, 528, 2002.

  16. VETTER PH, VON PRITZBUER J, JUNGMANN K, KROPP P, KOLLER O: The validity of the ICD-10 classification of recurrent affective disorders: do endogenous and psychogenic depressions form a homogeneous diagnostic group? Psychopathology; 34 (1):36-42, 2001

  17. HILDEBRANDT MG, STEYERBERG EW, STAGE KB, PASSCHIER J, KRAGH-SØRENSEN P, DANISH UNIVERSITY ANTIDEPRESSANT GROUP: Are gender differences important for the Clinical Effects of Antidepressants? Am J Psychiatry, 160:1643-1650, 2003.

  18. THIELE J, HOLZINGER O: “Ueber o-diaminodibenzyl”. Annales Chemische Liebiegs, 305:96-102, 1899.

  19. AYD FJ: Amitriptyline (elavil) therapy for depressive reactions. Psychosomatics, 1:320-325, 1960.

  20. AYD FJ: Recognizing the Depressed Patient. Grune and Stratton, New York, 1961.

  21. HAMILTON ME: A Rating scale for Depression. J Neurology Neurosurgery Psychiatry, 23:56-62, 1960.

  22. ROTH M, GURNEY C, MOUNTJOY CQ: The newcastle rating scales. Acta Psychiatr Scand (Suppl), 310:42-54, 1983.

  23. KRAGH-SØRENSEN P: Monitoring plasma concentration of nortriptyline. Methodological, pharmacokinetic and clinical aspects. Dan Med Bull, 1985 (Thesis) 32 (1):29-53, 1984.

  24. HAMMER W, SJÖQVIST F: Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci, 6:1895-1903, 1967.

  25. ALEXANDERSON B: On Interindividual Variability in Plasma Levels of Nortriptyline and Desmethylimipramine in Man: A Pharmacokinetic and Genetic Study. Linköping University Medical Dissertations, 6:1-46, 1972a;.

  26. DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Clomipramine Dose-effect Study in Patients with Depression: Clinical end Points and Pharmacokinetics. Clin Pharmacol Ther, 66:152-65, 1999.

  27. KRAGH-SØRENSEN P, HANSEN CE, ÅSBERG M: Plasma levels of nortriptyline in the treatment of endogenous depression. Acta Psychiatr Scand, 49:444-56, 1973.

  28. KRAGH-SØRENSEN P, HANSEN CE, BAASTRUP PC, HVIDBERG EF: Self-inhibiting action of nortriptyline’s antidepressive effect at high plasma levels. A randomized, double-blind study controlled by plasma concentrations in patients with endogenous depression. Psychopharmacologia (Berl.), 45:305-12, 1976.

  29. BURROWS GD, BRUCE A, SCOGGINS BT, TURECEK LR, DAVIES B: Plasma nortriptyline and clinical response. Clin Pharmacol Ther, 16(4):639-44, 1974a.

  30. DANISH UNIVERSITY ANTIDEPRESSANT GROUP: Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology, 90:131-138, 1986.

  31. DANISH UNIVERSITY ANTIDEPRESSANT GROUP: Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disorders, 18:289-299, 1990.

  32. STAGE KB, BECH P, GRAM LF, KRAGH-SØRENSEN P, ROSENBERG C, OHRBERG S: Are inpatients depressives more often of the melancholic subtype? Danish University Antidepressant Group. Acta Psychiatr Scand, 98(6):432-436, 1998.

  33. HAMILTON M: Development of a rating scale for primary depressive illness. British J Social Clinical Psychology, 6:278- 296, 1967.

  34. GUERNEY C: Diagnostic Scales for Affective Disorders. Proc 5th World Conference of Psychiatry, 130, Mexico City, 1971.

  35. STAGE KB, KRAGH-SØRENSEN P: Data to be published.




2020     |     www.medigraphic.com